- Home
- GB vs SDGR Comparison
GB vs SDGR Comparison
Compare GB & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GB
- SDGR
- Stock Information
- Founded
- GB 1980
- SDGR 1990
- Country
- GB Switzerland
- SDGR United States
- Employees
- GB N/A
- SDGR N/A
- Industry
- GB EDP Services
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- GB Technology
- SDGR Health Care
- Exchange
- GB Nasdaq
- SDGR Nasdaq
- Market Cap
- GB 1.5B
- SDGR 1.7B
- IPO Year
- GB N/A
- SDGR 2020
- Fundamental
- Price
- GB $7.44
- SDGR $21.62
- Analyst Decision
- GB Buy
- SDGR Buy
- Analyst Count
- GB 1
- SDGR 5
- Target Price
- GB $6.00
- SDGR $32.80
- AVG Volume (30 Days)
- GB 78.2K
- SDGR 1.2M
- Earning Date
- GB 06-09-2025
- SDGR 05-07-2025
- Dividend Yield
- GB N/A
- SDGR N/A
- EPS Growth
- GB 192.38
- SDGR N/A
- EPS
- GB 0.27
- SDGR N/A
- Revenue
- GB $503,508,645.00
- SDGR $230,492,000.00
- Revenue This Year
- GB $23.51
- SDGR $24.71
- Revenue Next Year
- GB $12.05
- SDGR $17.64
- P/E Ratio
- GB $27.36
- SDGR N/A
- Revenue Growth
- GB 20.43
- SDGR 22.29
- 52 Week Low
- GB $4.29
- SDGR $16.60
- 52 Week High
- GB $8.00
- SDGR $28.47
- Technical
- Relative Strength Index (RSI)
- GB 54.96
- SDGR 41.07
- Support Level
- GB $7.40
- SDGR $21.13
- Resistance Level
- GB $7.45
- SDGR $22.00
- Average True Range (ATR)
- GB 0.02
- SDGR 1.03
- MACD
- GB -0.00
- SDGR -0.23
- Stochastic Oscillator
- GB 70.00
- SDGR 30.11
About GB Global Blue Group Holding AG
Global Blue Group Holding AG offers a seamless shopping and payment journey for tourists and also provides a wide range of Added-Value Payment Solutions for all the stakeholders involved, including retailers and international shoppers. The company connect thousands of retailers, acquirers, and hotels with nearly 80 million consumers across more than 50 countries, in three industries: Tax Free Shopping, Payments and Post-Purchase solutions.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.